Stock Traders Purchase Large Volume of Call Options on Sangamo Therapeutics (NASDAQ:SGMO)

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) saw some unusual options trading on Monday. Stock traders bought 11,259 call options on the stock. This is an increase of approximately 2,053% compared to the typical volume of 523 call options.

Sangamo Therapeutics Price Performance

Shares of Sangamo Therapeutics stock opened at $0.52 on Wednesday. The business has a fifty day simple moving average of $0.81 and a two-hundred day simple moving average of $0.59. Sangamo Therapeutics has a 1 year low of $0.29 and a 1 year high of $1.78. The company has a market capitalization of $93.19 million, a price-to-earnings ratio of -0.35 and a beta of 1.39.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings results on Wednesday, March 13th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.09). The business had revenue of $2.04 million for the quarter, compared to analyst estimates of $8.96 million. Sangamo Therapeutics had a negative net margin of 146.30% and a negative return on equity of 82.17%. As a group, equities analysts anticipate that Sangamo Therapeutics will post -0.54 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on SGMO shares. StockNews.com started coverage on Sangamo Therapeutics in a report on Tuesday, February 13th. They issued a “sell” rating for the company. HC Wainwright reissued a “buy” rating and issued a $5.00 price objective (up previously from $3.00) on shares of Sangamo Therapeutics in a report on Tuesday, March 19th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and set a $2.00 price target on shares of Sangamo Therapeutics in a report on Thursday, March 14th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $4.93.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Acadian Asset Management LLC increased its position in Sangamo Therapeutics by 3.7% during the 3rd quarter. Acadian Asset Management LLC now owns 2,927,769 shares of the biopharmaceutical company’s stock worth $1,753,000 after buying an additional 105,789 shares during the period. Assenagon Asset Management S.A. increased its position in shares of Sangamo Therapeutics by 14.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 1,033,322 shares of the biopharmaceutical company’s stock worth $561,000 after purchasing an additional 129,811 shares during the period. Vanguard Personalized Indexing Management LLC bought a new position in shares of Sangamo Therapeutics in the third quarter worth $26,000. Golden State Equity Partners increased its position in shares of Sangamo Therapeutics by 22.5% in the third quarter. Golden State Equity Partners now owns 166,265 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 30,500 shares during the period. Finally, SG Americas Securities LLC increased its position in shares of Sangamo Therapeutics by 103.9% in the fourth quarter. SG Americas Securities LLC now owns 180,544 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 92,002 shares during the period. Institutional investors own 56.93% of the company’s stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.